Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland
One dose of pandemic influenza vaccine Pandemrix (GlaxoSmithKline) was offered to the entire population of Finland in 2009-10. We conducted a prospective clinical cohort study to determine the vaccine effectiveness in preventing febrile laboratory-confirmed influenza infection during the influenza s...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014, Vol.9 (9), p.e108538-e108538 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e108538 |
|---|---|
| container_issue | 9 |
| container_start_page | e108538 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Syrjänen, Ritva K Jokinen, Jukka Ziegler, Thedi Sundman, Jonas Lahdenkari, Mika Julkunen, Ilkka Kilpi, Terhi M |
| description | One dose of pandemic influenza vaccine Pandemrix (GlaxoSmithKline) was offered to the entire population of Finland in 2009-10. We conducted a prospective clinical cohort study to determine the vaccine effectiveness in preventing febrile laboratory-confirmed influenza infection during the influenza season 2009-10 and continued the study in 2010-11.
In total, 3,518 community dwelling adults aged 18-75 years living in Tampere city were enrolled. The participants were not assigned to any vaccination regimen, but they could participate in the study regardless of their vaccination status or intention to be vaccinated with the pandemic or seasonal influenza vaccine. They were asked to report if they received Pandemrix in 2009-10 and/or trivalent influenza vaccine in 2010-11. Vaccinations were verified from medical records. The participants were instructed to report all acute symptoms of respiratory tract infection with fever (at least 38°C) and pneumonias to the study staff. Nasal and oral swabs were obtained within 5-7 days after symptom onset and influenza-specific RNA was identified by reverse transcription polymerase chain reaction.
In 2009-10, the estimated vaccine effectiveness was 81% (95%CI 30-97). However, the vaccine effectiveness could not be estimated reliably, because only persons in prioritized groups were vaccinated before/during the first pandemic wave and many participants were enrolled when they already had the symptoms of A(H1N1)pdm09 influenza infection. In 2010-11, 2,276 participants continued the follow-up. The vaccine effectiveness, adjusted for potential confounding factors was 81% (95%CI 41-96) for Pandemrix only and 88% (95%CI 63-97) for either Pandemrix or trivalent influenza vaccine 2010-11 or both, respectively.
Vaccination with an AS03-adjuvanted pandemic vaccine in 2009-10 was still effective in preventing A(H1N1)pdm09 influenza during the following epidemic season in 2010-11.
ClinicalTrials.gov NCT01024725. NCT01206114. |
| doi_str_mv | 10.1371/journal.pone.0108538 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_plos_</sourceid><recordid>TN_cdi_plos_journals_1566321733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_a44dcd46d1ed46d785126d13604ee5ed</doaj_id><sourcerecordid>1566823145</sourcerecordid><originalsourceid>FETCH-LOGICAL-c526t-17ead4e4f01f80b6f625336c72f5e15ed4487d15c70d852b83a0b7301d937c913</originalsourceid><addsrcrecordid>eNptUk1v1DAQjRCIlsI_QGCJSy9Z_J0sh0qoaqFSJS5wtrz2eOuVNw52stLy-_hhdZpttUVcPJ7xe28-PFX1nuAFYQ35vIlj6nRY9LGDBSa4Fax9UZ2SJaO1pJi9PLqfVG9y3mBcIFK-rk6ooFKQVp5Wf6-cAzP4HXSQM4oO9bqzsPUGFYsy6BxLFuQ7F0bo_mi008b4Ai4h1CcoxMF3axT0KiY9xLSvTeycT1uwR6wC1nYMQ_6CNDLBd94UVRPvYhpQHka7R3ZMkxD0fs4_586IYrysaenwoaLpMnlkkrz2XSjBt9Urp0OGdwd7Vv26vvp5-b2-_fHt5vLrbW1Kv0NNGtCWA3eYuBavpJNUMCZNQ50AIsBy3jaWCNNg2wq6apnGq4ZhYpesMUvCzqqPs24fYlaHD8iKCCkZJQ1jBXEzI2zUG9Unv9Vpr6L26iEQ01rpNHgTQGnOrbFcWgLT2bSC0OIwiTlAKaZoXRyyjasyTFMGnXR4Jvr8pfN3ah13ipMWc7YsAucHgRR_j5AHtfXZQCgjgzjOdbeUES4K9NM_0P93x2eUSTHnBO6pGILVtJSPLDUtpTosZaF9OG7kifS4heweKB3hgA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1566321733</pqid></control><display><type>article</type><title>Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Syrjänen, Ritva K ; Jokinen, Jukka ; Ziegler, Thedi ; Sundman, Jonas ; Lahdenkari, Mika ; Julkunen, Ilkka ; Kilpi, Terhi M</creator><contributor>Marques, Ernesto T. A.</contributor><creatorcontrib>Syrjänen, Ritva K ; Jokinen, Jukka ; Ziegler, Thedi ; Sundman, Jonas ; Lahdenkari, Mika ; Julkunen, Ilkka ; Kilpi, Terhi M ; Marques, Ernesto T. A.</creatorcontrib><description>One dose of pandemic influenza vaccine Pandemrix (GlaxoSmithKline) was offered to the entire population of Finland in 2009-10. We conducted a prospective clinical cohort study to determine the vaccine effectiveness in preventing febrile laboratory-confirmed influenza infection during the influenza season 2009-10 and continued the study in 2010-11.
In total, 3,518 community dwelling adults aged 18-75 years living in Tampere city were enrolled. The participants were not assigned to any vaccination regimen, but they could participate in the study regardless of their vaccination status or intention to be vaccinated with the pandemic or seasonal influenza vaccine. They were asked to report if they received Pandemrix in 2009-10 and/or trivalent influenza vaccine in 2010-11. Vaccinations were verified from medical records. The participants were instructed to report all acute symptoms of respiratory tract infection with fever (at least 38°C) and pneumonias to the study staff. Nasal and oral swabs were obtained within 5-7 days after symptom onset and influenza-specific RNA was identified by reverse transcription polymerase chain reaction.
In 2009-10, the estimated vaccine effectiveness was 81% (95%CI 30-97). However, the vaccine effectiveness could not be estimated reliably, because only persons in prioritized groups were vaccinated before/during the first pandemic wave and many participants were enrolled when they already had the symptoms of A(H1N1)pdm09 influenza infection. In 2010-11, 2,276 participants continued the follow-up. The vaccine effectiveness, adjusted for potential confounding factors was 81% (95%CI 41-96) for Pandemrix only and 88% (95%CI 63-97) for either Pandemrix or trivalent influenza vaccine 2010-11 or both, respectively.
Vaccination with an AS03-adjuvanted pandemic vaccine in 2009-10 was still effective in preventing A(H1N1)pdm09 influenza during the following epidemic season in 2010-11.
ClinicalTrials.gov NCT01024725. NCT01206114.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0108538</identifier><identifier>PMID: 25265186</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Adults ; Aged ; Biology and Life Sciences ; Cohort analysis ; Cohort Studies ; Epidemics ; Female ; Fever ; Finland - epidemiology ; Humans ; Infections ; Influenza ; Influenza A Virus, H1N1 Subtype - immunology ; Influenza Vaccines - therapeutic use ; Influenza, Human - epidemiology ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; Male ; Medical records ; Medicine and Health Sciences ; Middle Aged ; Motivation ; Pandemics ; Polymerase chain reaction ; Prospective Studies ; Respiratory tract ; Respiratory tract diseases ; Reverse transcription ; Ribonucleic acid ; RNA ; Seasons ; Vaccination ; Vaccine efficacy ; Vaccines ; Viruses ; Womens health ; Young Adult</subject><ispartof>PloS one, 2014, Vol.9 (9), p.e108538-e108538</ispartof><rights>2014 Syrjänen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Syrjänen et al 2014 Syrjänen et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c526t-17ead4e4f01f80b6f625336c72f5e15ed4487d15c70d852b83a0b7301d937c913</citedby><cites>FETCH-LOGICAL-c526t-17ead4e4f01f80b6f625336c72f5e15ed4487d15c70d852b83a0b7301d937c913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180439/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180439/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,2103,2929,4025,23871,27928,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25265186$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Marques, Ernesto T. A.</contributor><creatorcontrib>Syrjänen, Ritva K</creatorcontrib><creatorcontrib>Jokinen, Jukka</creatorcontrib><creatorcontrib>Ziegler, Thedi</creatorcontrib><creatorcontrib>Sundman, Jonas</creatorcontrib><creatorcontrib>Lahdenkari, Mika</creatorcontrib><creatorcontrib>Julkunen, Ilkka</creatorcontrib><creatorcontrib>Kilpi, Terhi M</creatorcontrib><title>Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>One dose of pandemic influenza vaccine Pandemrix (GlaxoSmithKline) was offered to the entire population of Finland in 2009-10. We conducted a prospective clinical cohort study to determine the vaccine effectiveness in preventing febrile laboratory-confirmed influenza infection during the influenza season 2009-10 and continued the study in 2010-11.
In total, 3,518 community dwelling adults aged 18-75 years living in Tampere city were enrolled. The participants were not assigned to any vaccination regimen, but they could participate in the study regardless of their vaccination status or intention to be vaccinated with the pandemic or seasonal influenza vaccine. They were asked to report if they received Pandemrix in 2009-10 and/or trivalent influenza vaccine in 2010-11. Vaccinations were verified from medical records. The participants were instructed to report all acute symptoms of respiratory tract infection with fever (at least 38°C) and pneumonias to the study staff. Nasal and oral swabs were obtained within 5-7 days after symptom onset and influenza-specific RNA was identified by reverse transcription polymerase chain reaction.
In 2009-10, the estimated vaccine effectiveness was 81% (95%CI 30-97). However, the vaccine effectiveness could not be estimated reliably, because only persons in prioritized groups were vaccinated before/during the first pandemic wave and many participants were enrolled when they already had the symptoms of A(H1N1)pdm09 influenza infection. In 2010-11, 2,276 participants continued the follow-up. The vaccine effectiveness, adjusted for potential confounding factors was 81% (95%CI 41-96) for Pandemrix only and 88% (95%CI 63-97) for either Pandemrix or trivalent influenza vaccine 2010-11 or both, respectively.
Vaccination with an AS03-adjuvanted pandemic vaccine in 2009-10 was still effective in preventing A(H1N1)pdm09 influenza during the following epidemic season in 2010-11.
ClinicalTrials.gov NCT01024725. NCT01206114.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Biology and Life Sciences</subject><subject>Cohort analysis</subject><subject>Cohort Studies</subject><subject>Epidemics</subject><subject>Female</subject><subject>Fever</subject><subject>Finland - epidemiology</subject><subject>Humans</subject><subject>Infections</subject><subject>Influenza</subject><subject>Influenza A Virus, H1N1 Subtype - immunology</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention & control</subject><subject>Male</subject><subject>Medical records</subject><subject>Medicine and Health Sciences</subject><subject>Middle Aged</subject><subject>Motivation</subject><subject>Pandemics</subject><subject>Polymerase chain reaction</subject><subject>Prospective Studies</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Reverse transcription</subject><subject>Ribonucleic acid</subject><subject>RNA</subject><subject>Seasons</subject><subject>Vaccination</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Viruses</subject><subject>Womens health</subject><subject>Young Adult</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNptUk1v1DAQjRCIlsI_QGCJSy9Z_J0sh0qoaqFSJS5wtrz2eOuVNw52stLy-_hhdZpttUVcPJ7xe28-PFX1nuAFYQ35vIlj6nRY9LGDBSa4Fax9UZ2SJaO1pJi9PLqfVG9y3mBcIFK-rk6ooFKQVp5Wf6-cAzP4HXSQM4oO9bqzsPUGFYsy6BxLFuQ7F0bo_mi008b4Ai4h1CcoxMF3axT0KiY9xLSvTeycT1uwR6wC1nYMQ_6CNDLBd94UVRPvYhpQHka7R3ZMkxD0fs4_586IYrysaenwoaLpMnlkkrz2XSjBt9Urp0OGdwd7Vv26vvp5-b2-_fHt5vLrbW1Kv0NNGtCWA3eYuBavpJNUMCZNQ50AIsBy3jaWCNNg2wq6apnGq4ZhYpesMUvCzqqPs24fYlaHD8iKCCkZJQ1jBXEzI2zUG9Unv9Vpr6L26iEQ01rpNHgTQGnOrbFcWgLT2bSC0OIwiTlAKaZoXRyyjasyTFMGnXR4Jvr8pfN3ah13ipMWc7YsAucHgRR_j5AHtfXZQCgjgzjOdbeUES4K9NM_0P93x2eUSTHnBO6pGILVtJSPLDUtpTosZaF9OG7kifS4heweKB3hgA</recordid><startdate>2014</startdate><enddate>2014</enddate><creator>Syrjänen, Ritva K</creator><creator>Jokinen, Jukka</creator><creator>Ziegler, Thedi</creator><creator>Sundman, Jonas</creator><creator>Lahdenkari, Mika</creator><creator>Julkunen, Ilkka</creator><creator>Kilpi, Terhi M</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>2014</creationdate><title>Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland</title><author>Syrjänen, Ritva K ; Jokinen, Jukka ; Ziegler, Thedi ; Sundman, Jonas ; Lahdenkari, Mika ; Julkunen, Ilkka ; Kilpi, Terhi M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c526t-17ead4e4f01f80b6f625336c72f5e15ed4487d15c70d852b83a0b7301d937c913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Biology and Life Sciences</topic><topic>Cohort analysis</topic><topic>Cohort Studies</topic><topic>Epidemics</topic><topic>Female</topic><topic>Fever</topic><topic>Finland - epidemiology</topic><topic>Humans</topic><topic>Infections</topic><topic>Influenza</topic><topic>Influenza A Virus, H1N1 Subtype - immunology</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention & control</topic><topic>Male</topic><topic>Medical records</topic><topic>Medicine and Health Sciences</topic><topic>Middle Aged</topic><topic>Motivation</topic><topic>Pandemics</topic><topic>Polymerase chain reaction</topic><topic>Prospective Studies</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Reverse transcription</topic><topic>Ribonucleic acid</topic><topic>RNA</topic><topic>Seasons</topic><topic>Vaccination</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Viruses</topic><topic>Womens health</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Syrjänen, Ritva K</creatorcontrib><creatorcontrib>Jokinen, Jukka</creatorcontrib><creatorcontrib>Ziegler, Thedi</creatorcontrib><creatorcontrib>Sundman, Jonas</creatorcontrib><creatorcontrib>Lahdenkari, Mika</creatorcontrib><creatorcontrib>Julkunen, Ilkka</creatorcontrib><creatorcontrib>Kilpi, Terhi M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Syrjänen, Ritva K</au><au>Jokinen, Jukka</au><au>Ziegler, Thedi</au><au>Sundman, Jonas</au><au>Lahdenkari, Mika</au><au>Julkunen, Ilkka</au><au>Kilpi, Terhi M</au><au>Marques, Ernesto T. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014</date><risdate>2014</risdate><volume>9</volume><issue>9</issue><spage>e108538</spage><epage>e108538</epage><pages>e108538-e108538</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>One dose of pandemic influenza vaccine Pandemrix (GlaxoSmithKline) was offered to the entire population of Finland in 2009-10. We conducted a prospective clinical cohort study to determine the vaccine effectiveness in preventing febrile laboratory-confirmed influenza infection during the influenza season 2009-10 and continued the study in 2010-11.
In total, 3,518 community dwelling adults aged 18-75 years living in Tampere city were enrolled. The participants were not assigned to any vaccination regimen, but they could participate in the study regardless of their vaccination status or intention to be vaccinated with the pandemic or seasonal influenza vaccine. They were asked to report if they received Pandemrix in 2009-10 and/or trivalent influenza vaccine in 2010-11. Vaccinations were verified from medical records. The participants were instructed to report all acute symptoms of respiratory tract infection with fever (at least 38°C) and pneumonias to the study staff. Nasal and oral swabs were obtained within 5-7 days after symptom onset and influenza-specific RNA was identified by reverse transcription polymerase chain reaction.
In 2009-10, the estimated vaccine effectiveness was 81% (95%CI 30-97). However, the vaccine effectiveness could not be estimated reliably, because only persons in prioritized groups were vaccinated before/during the first pandemic wave and many participants were enrolled when they already had the symptoms of A(H1N1)pdm09 influenza infection. In 2010-11, 2,276 participants continued the follow-up. The vaccine effectiveness, adjusted for potential confounding factors was 81% (95%CI 41-96) for Pandemrix only and 88% (95%CI 63-97) for either Pandemrix or trivalent influenza vaccine 2010-11 or both, respectively.
Vaccination with an AS03-adjuvanted pandemic vaccine in 2009-10 was still effective in preventing A(H1N1)pdm09 influenza during the following epidemic season in 2010-11.
ClinicalTrials.gov NCT01024725. NCT01206114.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>25265186</pmid><doi>10.1371/journal.pone.0108538</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014, Vol.9 (9), p.e108538-e108538 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1566321733 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Adolescent Adult Adults Aged Biology and Life Sciences Cohort analysis Cohort Studies Epidemics Female Fever Finland - epidemiology Humans Infections Influenza Influenza A Virus, H1N1 Subtype - immunology Influenza Vaccines - therapeutic use Influenza, Human - epidemiology Influenza, Human - immunology Influenza, Human - prevention & control Male Medical records Medicine and Health Sciences Middle Aged Motivation Pandemics Polymerase chain reaction Prospective Studies Respiratory tract Respiratory tract diseases Reverse transcription Ribonucleic acid RNA Seasons Vaccination Vaccine efficacy Vaccines Viruses Womens health Young Adult |
| title | Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T20%3A11%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20pandemic%20and%20seasonal%20influenza%20vaccines%20in%20preventing%20laboratory-confirmed%20influenza%20in%20adults:%20a%20clinical%20cohort%20study%20during%20epidemic%20seasons%202009-2010%20and%202010-2011%20in%20Finland&rft.jtitle=PloS%20one&rft.au=Syrj%C3%A4nen,%20Ritva%20K&rft.date=2014&rft.volume=9&rft.issue=9&rft.spage=e108538&rft.epage=e108538&rft.pages=e108538-e108538&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0108538&rft_dat=%3Cproquest_plos_%3E1566823145%3C/proquest_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1566321733&rft_id=info:pmid/25265186&rft_doaj_id=oai_doaj_org_article_a44dcd46d1ed46d785126d13604ee5ed&rfr_iscdi=true |